FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis
NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S.
NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S.
On July 28th in South Africa, more than 100 members of the TB research community marched under the Louder than
July 18, 2019—Tuberculosis (TB) is the leading infectious cause of death worldwide and the number one cause of death among
NEW YORK (June 25, 2019)—TB Alliance today announced the appointment of Eugene Sun, MD to the position of Senior Vice
The G20’s top health and health financing experts will assemble in Tokyo on the eve of the Osaka G20 heads
SYDNEY (June 18, 2019)—TB Alliance today announced that one million treatment courses of child-friendly tuberculosis (TB) medicines have been ordered
NEW YORK (June 12, 2019)—TB Alliance, a not-for-profit organization leading the development of new, improved and affordable tuberculosis (TB) treatments,
Investigational drug pretomanid, developed by non-profit TB Alliance, is under regulatory review for treatment of extensively drug-resistant tuberculosis and treatment-intolerant
Every year, more than ten million people worldwide contract tuberculosis (TB) and in 2017, 1.6 million people died as a
GENEVA (May 22, 2019) – This week at the Seventy-second World Health Assembly, TB Alliance is joining our partners in global health